Bragg의 용량-반응-시간모형으로 rocuronium의 동학-약역학모수의 추정과 모의실험 = Estimation and simulation of kinetic-pharmacodynamic parameters of rocuronium by Bragg’s dose-response-time model

다국어 초록 (Multilingual Abstract)

Background:The effect-time data involves some pharmacokinetic (PK) information. Bragg model could derive the information from pharmacodynamic (PD) data alone. After administering rocuronium, we collected tension data without these plasma concentration values. We determined kinetic-pharmacodynamic (K-PD) parameters, simulated the predictions of effect-time relation at different amount of dose, and validated the calculated infusion rates (IR) by comparing with IR directly measured.
Methods: Thirteen dexterous male patients were given rocuronium 300μg/kg during propofol-fentanyl anesthesia. Twitch tensions of the right adductor pollicis in response to supramaximal single twitch stimulation every 10 seconds were measured until muscle paralysis recovered by 70 ± 10% of control. The above data were fitted to Bragg equation, using Tablecurve3DⓇ. The parameters, k1, k2, IR50, and γ, were derived with either individual regression or population regression. The correlations between individual parameter and time, the simulation, and validation by infusing rocuronium 3.66μg/kg/min were examined.
Results: Based on population regression, IR50 was 3.70μg/kg/min, γ was 4.51, k1 (keo) was 0.71/min, and k2 (k10) was 0.022/min. The longer the duration of rocuronium action was, the smaller the values of IR50 and k2 were (correlation coefficient: −0.92, −0.61, respectively). ED50 calculated (= IR50/k2) was 168μg/kg. The effects of rocuronium 3.66μg/kg/min were estimated (45% by direct measurement, 49% by population parameters, and 21% by individual parameters).
Conclusions: The results of infusion rate validation suggests that population parameters may better be applicable than individual post hoc parameters to predicting the clinically relevant effect-time relations.(Anesth Pain Med 2011; 6: 67∼74)

참고문헌 (Reference)

1 Sheiner LB, "Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine" 25 : 358-371, 1979

2 Verotta D, "Simultaneous modeling of pharmacokinetics and pharmacodynamics: An improved algorithm" 3 : 345-349, 1987

3 Verotta D, "Semiparametric analysis of non-steady- state pharmacodynamic data" 19 : 61-712, 1991

4 Bock M, "Rocuronium potency and recovery characteristics during steady- state desflurane, sevoflurane, isoflurane or propofol anaesthesia" 84 : 43-47, 2000

5 Dragne A, "Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia" 49 : 353-360, 2002

6 Levy G, "Relationship between rate of elimination of tubocurarine and rate of decline of its pharmacological activity" 36 : 694-695, 1964

7 Kuipers JA, "Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: The influence of cardiac output" 94 : 47-55, 2001

8 Olkkola KT, "Quantifying the interaction of rocuronium (org 9426) with etomidate, fentanyl, midazolam, propofol, thiopental, and isoflurane using closed-loop feedback control of rocuronium infusion" 78 : 691-696, 1994

9 Torda TA, "Pharmacokinetics and pharmacodynamics of suxamethonium" 25 : 272-278, 1997

10 Plaud B, "Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans" 58 : 185-191, 1995

11 van Schaick EA, "Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N6-(p-sulphophenyl)adenosine in rats" 122 : 525-533, 1997

12 Zhu Y, "Pharmacokinetic-pharmacodynamic modeling of doxacurium: Effect of input rate" 25 : 23-37, 1997

13 Warwick NR, "Pharmacokinetic analysis of the effect of vecuronium in surgical patients: Pharmacokinetic and pharmacodynamic modeling without plasma concentrations" 88 : 874-884, 1998

14 Paul M, "Pharmacodynamic modeling of muscle relaxants: Effect of design issues on results" 96 : 711-717, 2002

15 Romberg R, "Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers" 99 : 788-798, 2003

16 Jacqmin P, "Modelling response time profiles in the absence of drug concentrations: Definition and performance evaluation of the K-PD model" 34 : 57-85, 2007

17 Gabrielsson J, "Modeling of dose-response-time data: Four examples of estimating the turnover parameters and generating kinetic functions from response profiles" 21 : 41-52, 2000

18 Levy G, "Kinetics of pharmacologic activity of succinylcholine in man" 56 : 1687-1688, 1967

19 이도경, "Isoflurane과 Propofol 마취 중 Rocuronium의 약역학" 대한마취과학회 42 (42): 455-460, 2002

20 Fuchs-Buder T, "Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: The stockholm revision" 51 : 789-808, 2007

21 Cortinez LI, "Estimation of the plasma effect-site equilibration rate constant (ke0) of rocuronium by the time of maximum effect: A comparison with non-parametric and parametric approaches" 99 : 679-685, 2007

22 Kansanaho M, "Dose-response and concentration-response relation of rocuronium infusion during propofol-nitrous oxide and isoflurane-nitrous oxide anaesthesia" 14 : 488-494, 1997

23 Gibaldi M, "Dose-dependent decline of pharmacologic effects of drugs with linear pharmacokinetic characteristics" 61 : 567-569, 1972

24 Bragg P, "Comparison of twitch depression of the adductor pollicis and the respiratory muscles. pharmacodynamic modeling without plasma concentrations" 80 : 310-319, 1994

25 Fisher DM, "Are plasma concentration values necessary for pharmacodynamic modeling of muscle relaxants" 86 : 567-575, 1997

26 Pillai G, "A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis" 58 : 618-631, 2004